LPTX Projected Dividend Yield
Leap Therapeutics Inc ( NASDAQ : LPTX )Leap Therapeutics is a biopharmaceutical company developing biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. Co.'s primary clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1. Co.'s second clinical stage program is FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface. Co. also has two preclinical antibody programs, FL-302 and FL-501. 20 YEAR PERFORMANCE RESULTS |
LPTX Dividend History Detail LPTX Dividend News LPTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |